Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research.
| Contributors |
|
ix | |
|
Assembly and Intracellular Trafficking of GABAA Receptors |
|
|
|
|
|
|
|
1 | (2) |
|
Assembly of GABAA Receptors |
|
|
3 | (5) |
|
Surface Targeting and Intracellular Sorting of GABAA Receptors |
|
|
8 | (3) |
|
GABAA Receptor-Clustering Proteins |
|
|
11 | (3) |
|
Endocytosis and Recycling of GABAA Receptors |
|
|
14 | (18) |
|
|
|
23 | (9) |
|
Subcellular Localization and Regulation of GABAA Receptors and Associated Proteins |
|
|
|
|
|
|
|
|
|
32 | (1) |
|
Functional Significance of GABAergic Inhibition in the Brain |
|
|
33 | (1) |
|
Structural Anatomy of GABAergic Synapses |
|
|
33 | (1) |
|
Structure of GABAA Receptors |
|
|
34 | (1) |
|
Subcellular Localization of GABAA Receptor Subtypes |
|
|
35 | (11) |
|
Factors Implicated in Exocytosis and Endocytosis of GABAA Receptors |
|
|
46 | (2) |
|
Synaptic Anchoring of GABAG Receptors |
|
|
48 | (1) |
|
GABAA Receptor-Associated Signaling Proteins |
|
|
49 | (1) |
|
|
|
50 | (4) |
|
|
|
54 | (12) |
|
|
|
54 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
66 | (2) |
|
Localization and Function of D1-like Receptors |
|
|
68 | (21) |
|
Development of Drugs for D1-like Receptors |
|
|
89 | (11) |
|
Therapeutic and Functional Actions of D1 Receptor Agonists and Antagonists |
|
|
100 | (16) |
|
Conclusions and Future Goals |
|
|
116 | (25) |
|
|
|
117 | (24) |
|
Molecular Modeling of Ligand-Gated Ion Channels: Progress and Challenges |
|
|
|
|
|
|
|
The Challenge of Modeling Transmembrane Ion Channels |
|
|
141 | (2) |
|
Overview of Molecular Modeling Principles |
|
|
143 | (5) |
|
Experimental Data: Techniques and Results |
|
|
148 | (7) |
|
|
|
155 | (6) |
|
|
|
161 | (7) |
|
|
|
162 | (6) |
|
Alzheimer's Disease: Its Diagnosis and Pathogenesis |
|
|
|
|
|
|
|
|
|
168 | (1) |
|
|
|
169 | (7) |
|
|
|
176 | (13) |
|
|
|
189 | (5) |
|
Inflammation and Anti-inflammatory Drugs |
|
|
194 | (3) |
|
|
|
197 | (1) |
|
|
|
197 | (22) |
|
|
|
201 | (18) |
|
DNA Arrays and Functional Genomics in Neurobiology |
|
|
|
|
|
|
|
|
|
|
|
|
|
219 | (2) |
|
DNA Array Formats and Technique |
|
|
221 | (11) |
|
Applications in Neurobiology |
|
|
232 | (12) |
|
|
|
244 | (4) |
|
|
|
248 | (7) |
|
|
|
248 | (7) |
| Index |
|
255 | (8) |
| Contents of Recent Volumes |
|
263 | |
Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinsons disease. He has spent the major part of his career at Kings College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of Kings College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.
Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinsons disease patient-carer groups across the UK.
